Arab Journal of Gastroenterology最新文献

{"title":"Safety and efficacy of linaclotide as an adjuvant for bowel preparation: A systematic review and meta-analysis","authors":"Ahmed Farag ,&nbsp;Amany Mahmoud Genidy ,&nbsp;Mahmoud Raslan ,&nbsp;Mohamed Nasr Gadelrab","doi":"10.1016/j.ajg.2025.09.017","DOIUrl":"10.1016/j.ajg.2025.09.017","url":null,"abstract":"<div><h3>Introduction</h3><div>High-volume polyethylene glycol (PEG) is widely used for bowel preparation, but its large volume and unpleasant taste are common drawbacks. These factors frequently lead to reduced patient adherence. Linaclotide, an FDA-approved drug for constipation, appears to offer a potential solution by lowering the amount of PEG needed.</div></div><div><h3>Methods</h3><div>Our search included MEDLINE through PubMed, Scopus, Web of Science (WOS), and Cochrane databases. Subgroup analysis was employed for additional stratification.</div></div><div><h3>Results</h3><div>The overall effect estimates regarding total BBPS score indicated no significant difference between the two groups [MD 0.19, 95 % CI (−0.37, 0.74), P = 0.51]. Further stratification showed linaclotide superiority over the control group with equal PEG dosage [MD 0.99, 95 % CI (0.69, 1.30), P &lt; 0.00001] and no difference compared to the group with double the PEG dosage [MD −0.27, 95 % CI (−0.59, 0.05], P = 0.10]. No statistically significant difference between the two groups was detected in adenoma detection, polyp detection, or cecal intubation time. Also, Linaclotide showed statistical superiority against all subgroups regarding withdrawal time. Moreover, linaclotide group showed a favoring statistically significant difference regarding nausea, vomiting, abdominal pain, bloating, and willingness to repeat the colonoscopy.</div></div><div><h3>Conclusion</h3><div>Linaclotide demonstrates superior efficacy compared to the control group with equal PEG doses and shows no statistically significant difference when compared to the group with double the PEG dosage, all while resulting in fewer adverse events.</div></div>","PeriodicalId":48674,"journal":{"name":"Arab Journal of Gastroenterology","volume":"26 4","pages":"Pages 462-472"},"PeriodicalIF":1.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145472303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methotrexate induced liver fibrosis is over estimated as assessed by transient elastography, acoustic radiation force impulse and serum markers","authors":"Hedy A. Badary ,&nbsp;Rasha Ahmed ,&nbsp;Samar K. Darweesh ,&nbsp;Zeinab Zakaria ,&nbsp;Hanan Darweesh ,&nbsp;Hala Ramadan ,&nbsp;Rania Amin ,&nbsp;Naglaa Zayed ,&nbsp;Ayman Yosry ,&nbsp;Zeinab Abdellatif","doi":"10.1016/j.ajg.2025.06.001","DOIUrl":"10.1016/j.ajg.2025.06.001","url":null,"abstract":"<div><h3>Background and study aims</h3><div>Noninvasive assessment of liver fibrosis is critical for monitoring rheumatoid arthritis (RA) patients undergoing methotrexate (MTX). This study aimed to detect subclinical liver fibrosis induced by MTX assessed using FIB-4, APRI, transient elastography (TE), and acoustic radiation force impulse (ARFI) elastography.</div></div><div><h3>Patients and methods</h3><div>This retrospective cohort study enrolled 120 RA patients: 60 patients received MTX, and 60 received a combination of MTX and leflunomide (LEF). Liver fibrosis assessment was conducted using FIB-4, APRI, TE, and ARFI at the time of enrollment. Pretreatment FIB-4 and APRI were calculated retrospectively.</div></div><div><h3>Results</h3><div>Serum transaminase levels remained within normal ranges in both groups regardless of treatment or MTX duration. The DAS 28 score indicated that the patients were in remission at the study time. At baseline (prior to MTX administration), 114 patients (95 %) exhibited low fibrosis risk according to FIB-4, whereas 6 patients (5 %) were classified as intermediate risk. APRI indicated that 117 patients<!--> <!-->(97.5 %) exhibited non-significant fibrosis, whereas 3 (2.5 %) presented with significant fibrosis. Upon enrollment, there was a significant increase in FIB-4 scores compared to the baseline in both groups (0.56 vs. 0.72; P = 0.0002 and 0.65 vs. 0.76; P &lt; 0.001). However, values remained within non-significant ranges. The LEF and MTX combination significantly increased APRI (0.35 vs. 0.37; P = 0.006) without reaching thresholds for significant fibrosis. TE and ARFI indicated non-significant fibrosis (F0–F1) in 116 patients (96.7) (58 per group) and moderate fibrosis (F2) in 4 patients (3.3 %). The duration of MTX treatment emerged as a significant predictor of liver fibrosis, albeit mild, as demonstrated by logistic regression analysis (OR 1.15, P = 0.008).</div></div><div><h3>Conclusion</h3><div>The assessment of MTX-induced liver fibrosis in RA patients, using<!--> <!-->TE, ARFI, and serum markers, appears to be overestimated. Transaminases did not serve as predictors of liver disease or fibrosis severity in RA<!--> <!-->patients undergoing MTX<!--> <!-->treatment.</div></div>","PeriodicalId":48674,"journal":{"name":"Arab Journal of Gastroenterology","volume":"26 3","pages":"Pages 292-299"},"PeriodicalIF":1.1,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144602017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endoscopic treatment of gastrointestinal bleeding with gelatin sponge","authors":"Xianwen Guo ,&nbsp;Ronge Lei ,&nbsp;Jiao Li ,&nbsp;Qi He ,&nbsp;Guochen Shang ,&nbsp;Rong Lin ,&nbsp;Zhen Ding","doi":"10.1016/j.ajg.2025.01.011","DOIUrl":"10.1016/j.ajg.2025.01.011","url":null,"abstract":"<div><h3>Background and study aims</h3><div>Solid gelatin sponge is widely used in surgery but cannot be used endoscopically. A fluid gelatin sponge (FGS) was prepared for this research.</div></div><div><h3>Material and methods</h3><div>The hemostatic effect of the FGS on gastrointestinal wound bleeding was evaluated through pig experiments. One bleeding ulcer was randomly sprayed with FGS, and the other bleeding ulcer was sprayed with normal saline. Endoscopy was performed after 2 h, 3 days, and 14 days for the evaluation of the hemostatic effect and the quality of ulcer healing. At 14 days, the central tissue of the ulcer was biopsied. In addition, FGS dynamic coagulation and gastric juice mixing experiments were performed in vitro.</div></div><div><h3>Result</h3><div>The FGS group had a higher initial hemostasis success rate and shorter hemostasis time than the NC group. The rebleeding rate of ulcer was significantly higher in the NC group than that in the FGS group (75 % vs. 25 %). Fourteen days after the operation, the ulcer healing quality in the FGS group was significantly better than that in the control group. The degree of inflammation and fibrosis of ulcer tissues in the FGS group was lower, whereas microvessel density was higher. In addition, IL-6 mRNA levels in ulcerated tissues of the FGS group were not significantly different from those in the NC group and normal group (P&gt;0.05).</div></div><div><h3>Conclusion</h3><div>The adoption of self-made FGS under endoscopy achieved a good hemostatic effect on intestinal bleeding wounds, inhibiting rebleeding and accelerating wound healing.</div></div>","PeriodicalId":48674,"journal":{"name":"Arab Journal of Gastroenterology","volume":"26 3","pages":"Pages 300-307"},"PeriodicalIF":1.1,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144530458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PIMREG modulation of PI3K/Akt pathway enhances sorafenib resistance in Huh7 cells","authors":"Lei Zhang ,&nbsp;Aijun Gao ,&nbsp;Kaiyun Peng","doi":"10.1016/j.ajg.2025.05.002","DOIUrl":"10.1016/j.ajg.2025.05.002","url":null,"abstract":"<div><h3>Background and study aims</h3><div>Sorafenib, as a novel multi-targeted oral tumor chemotherapeutic drug, has been found to exert an impact on the inhibition of cancer growth. Phosphatidylinositol-binding reticulin assembly protein interacting with mitotic regulatory factors (PIMREG) is strongly associated with oncology to drug resistance. However, how PIMREG modulates therapy tolerance to sorafenib in HCC and its potential regulatory mechanisms remain unclear. This study is abouta mechanistic approach to examine the action and mechanism of PIMREG in HCC-mediated sorafenib resistance.</div></div><div><h3>Material and methods</h3><div>The human hepatocellular carcinoma sensitive cell line Huh7 and drug-resistant cell line Huh7/SFB were used for the study, and different rates of PIMREG expansion in both cells were detected. Next, the study transfected PIMREG overexpression and interference vector into hepatoma cell line Huh7/SFB, and acted on the cells with solafenib exhibiting a concentration gradient. The growth inhibition rate and IC50 value of cells were detected by MTT method to determine the concentration and time of drug addition. Then, this study employed MTT, qRT-PCR, flow cytometry, and Western blot to assay the growth of these cells, which were induced through overexpression and disruption of PIMREG, in combination with sorafenib. The study also constructed an in vivo mouse tire sample test in order to investigate the influence of PIMREG upon the in vitro efficacy of sorafenib. In addition, the study used LY294002 inhibitors to explore the molecular mechanisms of PIMREG-mediated resistance to sorafenib in Huh7/SFB cells.</div></div><div><h3>Results</h3><div>The expression level of PIMREG in cells of the Huh7/SFB resistant strain was clearly higher than that in cells of the sensitive strain Huh7. After transfection of sh-PIMREG, the IC50 value decreased significantly, while OE-PIMREG significantly increased the IC50 value of sorafinib. Compared with the control group, inhibition of cell proliferation by sorafenib was enhanced after interference with PIMREG, while the effect of overexpression of PIMREG was on the contrary. The efficacy of sorafenib was enhanced by knockout of PIMREG in living organisms. In addition, the PI3K/AKT signal pathway was necessary for PIMREG-induced sorafenib resistance. Subsequently, PIMREG regulated sorafenib-induced inhibition of the PI3K/AKT signaling pathway, and LY294002 blocked the signal pathway to reduce PIMREG-induced resistance.</div></div><div><h3>Conclusion</h3><div>All in all, an increase in HCC resistance to sorafenib via the PIMREG-mediated PI3K/AKT pathway suggests that PIMREG is a key tumor-associated gene with significant implications for sorafenib resistance in tumor cells.</div></div>","PeriodicalId":48674,"journal":{"name":"Arab Journal of Gastroenterology","volume":"26 3","pages":"Pages 241-249"},"PeriodicalIF":1.1,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144530530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of latiglutenase in treating celiac disease: a systematic review and meta-analysis of randomized controlled trials","authors":"Asmaa M. Albasha Hejazi ,&nbsp;Mohamed Abd–ElGawad ,&nbsp;Ahmed Farid Gadelmawla ,&nbsp;Amany Abd-Elhafeez ,&nbsp;Heba Mahmoud Abdelraheem ,&nbsp;Ekram Hasanin ,&nbsp;Majd Kahaleh ,&nbsp;Bayan Alnaser ,&nbsp;Nazir Ibrahim","doi":"10.1016/j.ajg.2025.05.001","DOIUrl":"10.1016/j.ajg.2025.05.001","url":null,"abstract":"<div><h3>Background</h3><div>Celiac Disease (CeD) is a chronic immunological illness. So far, the only known treatment for CeD is a lifelong gluten-free diet. However, enzyme therapy was proposed as an alternative. This study aimed to assess the impact of Latiglutenase, an example of enzyme therapy, on CeD patients compared to a placebo through a comprehensive assessment of existing literature.</div></div><div><h3>Methods</h3><div>We searched the following databases: Scopus, Web of Science, Cochrane Central Library, and PubMed from their respective inception date to February 18, 2024. We included randomized controlled trials comparing Latiglutenase with a placebo, with accessible full text in English. Outcomes included symptoms and histological findings improvement. We used the Revman 5.4 software to conduct the statistical analysis. For assessing the risk of bias, we utilized the Cochrane Collaboration tool ROB 2.</div></div><div><h3>Results</h3><div>Data from five randomized controlled trials was collected, with 1003 participants meeting the inclusion criteria. We found no significant differences between the Latiglutenase group and placebo group regarding adverse events like bloating (P = 0.55), nausea (P = 0.43), vomiting (P = 0.39), diarrhea (P = 0.83), tiredness (P = 0.83), headache (P = 0.08), and flatulence (P = 0.64); and histological findings like villous height to crypt depth ratio (Vh:Cd ratio), and intraepithelial lymphocytes (IELs) (mean difference (MD) = 0.19, 95 % confidence interval (CI) = [−0.24,0.62]; P = 0.39 and MD = −10.78, 95 % CI = [−26.97, 5.40]; P = 0.19, respectively).</div></div><div><h3>Conclusion</h3><div>Latiglutenase did not significantly improve adverse events or histological findings in CeD patients. However, there is still a need for further RCTs to evaluate its effectiveness more precisely.</div></div>","PeriodicalId":48674,"journal":{"name":"Arab Journal of Gastroenterology","volume":"26 3","pages":"Pages 225-233"},"PeriodicalIF":1.1,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144530457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology and drug resistance of Salmonella and Aeromonas in the faecal samples from pediatric patients with infectious diarrhea at a children’s medical center in Suzhou, China from 2016 to 2023","authors":"Yuanyuan Gao ,&nbsp;Hanyue Yang ,&nbsp;Zidan Liu ,&nbsp;Yunzhong Wang ,&nbsp;Xin Zhang ,&nbsp;Yang Li","doi":"10.1016/j.ajg.2025.04.003","DOIUrl":"10.1016/j.ajg.2025.04.003","url":null,"abstract":"<div><h3>Background and study aims</h3><div>Diarrheal diseases among children represent a prominent global health challenge, leading to significant morbidity and mortality, especially in emerging economies. This study aims to investigate the prevalence and trends of bacterial pathogens causing diarrhea in children.</div></div><div><h3>Patients and methods</h3><div>We retrospectively conducted an analysis of outpatient and inpatient records at Children’s Hospital of Soochow University, from 2016 to 2023. Only children presenting with diarrhea were included in the study. The clinical microbiology laboratory performed cultivation and identification of faecal samples, along with drug susceptibility testing on isolated <em>Salmonella</em> and <em>Aeromonas</em> species.</div></div><div><h3>Results</h3><div>A total of 2,163 cases of <em>Salmonella</em>, 334 cases of <em>Aeromonas</em> were identified from 13,662 faecal culture samples. There was a noticeable annual increase in the detection of <em>Salmonella</em> and <em>Aeromonas</em> in recent years. Samples from children with the age group of 12 to 35 months were more likely to be positive for <em>Salmonella</em> than those from children with other age groups, whereas those with the age group of 6 to 11 months were more prone to <em>Aeromonas</em>. Samples taken in the summer were most likely to be positive for <em>Salmonella</em> and <em>Aeromonas</em>. Samples from hospitalized children were considerably more likely to be positive for <em>Salmonella</em> than those from outpatient children. <em>Salmonella</em>-infected children were predominantly admitted to departments of digestion and infectious diseases, whereas <em>Aeromonas</em>-infected patients were spread across various clinics, especially gastroenterology. <em>Salmonella</em> Group B and <em>Aeromonas punctata (caviae)</em> were the most prevalent strains among their respective species. Notably, the resistance of <em>Salmonella</em> and <em>Aeromonas</em> to fluoroquinolone antibiotics has been escalating since 2018, with inpatients exhibiting a significantly higher rate of drug resistance compared to outpatients.</div></div><div><h3>Conclusion</h3><div>The integration of bacterial identification and drug susceptibility testing is crucial for the effective prevention and management of childhood diarrhea. The use of targeted antibiotics is essential to curb the rise of drug-resistant strains and ensure effective treatment outcomes.</div></div>","PeriodicalId":48674,"journal":{"name":"Arab Journal of Gastroenterology","volume":"26 3","pages":"Pages 254-261"},"PeriodicalIF":1.1,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144530459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expansively splenic reflective foci: A case-based résumé","authors":"Omkolsoum Alhaddad ,&nbsp;Maha Elsabaawy ,&nbsp;Mohamed Eissa ,&nbsp;Rasha Abdelhafeez ,&nbsp;Eman Rewisha ,&nbsp;Imam Waked","doi":"10.1016/j.ajg.2025.04.002","DOIUrl":"10.1016/j.ajg.2025.04.002","url":null,"abstract":"<div><div>Splenic siderotic foci are scar tissue composing freckles, usually less than 1 cm. They turn reflective after further deposition of calcium. These foci are also known as Gamna-Gandy bodies and are most encountered in severe and long-standing portal hypertensive – congestive splenomegaly. Herein, we present a case of an unusual sonographic depiction of reflective foci wholly embracing an average-sized spleen and imposing a clinical dispute.</div></div>","PeriodicalId":48674,"journal":{"name":"Arab Journal of Gastroenterology","volume":"26 3","pages":"Pages 311-313"},"PeriodicalIF":1.1,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144530460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Esophageal localized muscular defect observed during endoscopic submucosal dissection","authors":"Shinya Taki,&nbsp;Mikitaka Iguchi,&nbsp;Masayuki Kitano","doi":"10.1016/j.ajg.2025.01.001","DOIUrl":"10.1016/j.ajg.2025.01.001","url":null,"abstract":"","PeriodicalId":48674,"journal":{"name":"Arab Journal of Gastroenterology","volume":"26 3","pages":"Pages 308-310"},"PeriodicalIF":1.1,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144081415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The efficacy and safety of venous thromboembolism prophylaxis among hospitalized cirrhotic patients: Systematic review and meta-analysis","authors":"Abdel-Naser Elzouki ,&nbsp;Mohamed Nabil Elshafei ,&nbsp;Islam Elzouki ,&nbsp;Munir Abu-Ageila ,&nbsp;Muhammad Aamir Waheed ,&nbsp;Elmukhtar Habas ,&nbsp;Suhail Doi ,&nbsp;Mohammed I. Danjuma","doi":"10.1016/j.ajg.2025.01.010","DOIUrl":"10.1016/j.ajg.2025.01.010","url":null,"abstract":"<div><h3>Background and study aims</h3><div>This meta-analysis aims to evaluate the effect of prophylactic anticoagulation on incidence of venous thromboembolism (VTE), bleeding events, and mortality in hospitalized cirrhotic patients.</div></div><div><h3>Methods</h3><div>We utilized the following databases (EMBASE, PubMed, MedRxiv and google-scholar) to search for studies that satisfied the reviewers pre-specified inclusion criteria. The incidence of VTE, bleeding risks, and mortality were assessed using a quality effect meta-analytic model.</div></div><div><h3>Results</h3><div>From screening of 539 studies, a total of 9 studies (n = 6275 patients) satisfied inclusion criteria. Our results suggested no significant difference in the primary outcome of VTE events in both groups of cirrhotic patients who received and did not receive anticoagulation for VTE prophylaxis, (OR:0.9, 95 % CI:0.50–1.62). Similarly, there was a non-significant reduced risk of bleeding events in hospitalized cirrhotic amongst patient cohorts receiving VTE prophylaxis compared to those who did not (OR:0.51, 95 % CI:0.22–1.14). Analysis of three studies showed no significant difference in mortality in both groups (OR 1.02, 95 % CI:0.8–1.31).</div></div><div><h3>Conclusion</h3><div>In a pooled examination of studies evaluating outcomes in patients exposed to VTE prophylactic anticoagulation, we found no significant difference in the burden of VTE or mortality between treated and untreated patients with chronic liver disease (CLD). The retrospective design of a plurality of studies enrolled in the review meant further prospective studies are needed to objectively ascertain the efficacy and safety of VTE prophylaxis amongst patient cohorts with CLD.</div></div>","PeriodicalId":48674,"journal":{"name":"Arab Journal of Gastroenterology","volume":"26 3","pages":"Pages 234-240"},"PeriodicalIF":1.1,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144053427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Choroidal vascular alterations in patients with Helicobacter pylori gastritis","authors":"Ali Küçüködük ,&nbsp;Enver Avcı","doi":"10.1016/j.ajg.2025.04.004","DOIUrl":"10.1016/j.ajg.2025.04.004","url":null,"abstract":"<div><h3>Background and study aims</h3><div>This study aims to examine the impact of Helicobacter pylori (<em>H. pylori</em>) gastritis, a condition that induces chronic inflammation in the body, on subfoveal choroidal thickness (SFCT) and choroidal vascular index (CVI) measurements.</div></div><div><h3>Patients and methods</h3><div>In this prospective study, data were collected from 76 patients who visited the gastroenterology clinic, had their <em>H. pylori</em> diagnosis confirmed through gastric biopsy, and had not yet received treatment. An additional 76 age- and gender-matched healthy individuals formed the control group. Subfoveal choroidal thickness (SFCT) was measured using enhanced depth imaging optical coherence tomography (EDI-OCT) (Spectralis, Heidelberg Engineering, Heidelberg, Germany). CVI measurements were obtained by dividing the subfoveal choroidal area in the EDI-OCT images into luminal and stromal areas using the image binarization technique.</div></div><div><h3>Results</h3><div>The mean SFCT was 359.14 ± 24.23 µm in the H. pylori-positive group and 353.62 ± 12.78 µm in the control group, with no statistically significant difference between the groups (p = 0.782). Similarly, the choroidal vascular index (CVI) was 0.63 in the H. pylori group and 0.62 in the control group, with no significant difference observed (p = 0.08).</div></div><div><h3>Conclusion</h3><div>Results indicate that SFCT and CVI measurements do not undergo significant changes during the active phase of <em>H. pylori</em> infection compared to the control group.</div></div>","PeriodicalId":48674,"journal":{"name":"Arab Journal of Gastroenterology","volume":"26 3","pages":"Pages 250-253"},"PeriodicalIF":1.1,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144021617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}